EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE

被引：0
|
作者：
Ducournau, P. [1 ]
Latimer, N. [2 ]
Sabate, E. [1 ]
Walzer, S. [1 ]
机构：
[1] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[2] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66575-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A471 / A472
页数：2
相关论文
共 50 条
  • [41] Cost-Effectiveness of Adjuvant FOLFOX and 5FU/LV Chemotherapy for Patients with Stage II Colon Cancer
    Ayvaci, Mehmet U. S.
    Shi, Jinghua
    Alagoz, Oguzhan
    Lubner, Sam J.
    MEDICAL DECISION MAKING, 2013, 33 (04) : 521 - 532
  • [42] Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer
    Kumar, Aalok
    Peixoto, Renata D.
    Kennecke, Hagen F.
    Renouf, Daniel J.
    Lim, Howard J.
    Gil, Sharlene
    Speers, Caroline H.
    Cheung, Winson Y.
    CLINICAL COLORECTAL CANCER, 2015, 14 (04) : 262 - 268
  • [43] Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer
    Degirmencioglu, Serkan
    Tanriverdi, Ozgur
    Demiray, Atike Gokcen
    Senol, Hande
    Dogu, Gamze Gokoz
    Yaren, Arzu
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (06) : 2507 - 2515
  • [44] CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis
    Alarid-Escudero, Fernando
    Schrag, Deborah
    Kuntz, Karen M.
    VALUE IN HEALTH, 2022, 25 (03) : 409 - 418
  • [45] FOLFOX4 in the Adjuvant Treatment of Colon Cancer in Asian Patients
    Lin, Yu-Lin
    Liang, Jin-Tung
    HEPATO-GASTROENTEROLOGY, 2012, 59 (114) : 400 - 404
  • [46] Pharmacoeconomic analysis of capecitabine in adjuvant treatment of stage III colon cancer in Taiwan
    Hsu, T. C.
    Chen, H. H.
    Chen, L. T.
    Changchien, C. R.
    Liu, M. C.
    Wang, H. M.
    Yang, L.
    VALUE IN HEALTH, 2007, 10 (03) : A11 - A12
  • [47] Standards in adjuvant treatment of stage II and III in colon cancer
    Labianca, Roberto
    Garassino, Marina Chiara
    ANNALS OF ONCOLOGY, 2006, 17 : 37 - 37
  • [48] Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
    Bai, Liangliang
    Zhang, Pengfei
    Zhou, Kexun
    Liao, Weiting
    Li, Qiu
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10419 - 10426
  • [49] Cost-analysis of xelox vs. folfox-4 ± bevacizumab (BEV) in metastatic colorectal cancer (MCRC) in an Italian hospital setting
    Garrison, L. P.
    Giuliani, G.
    Ducournau, P.
    Cirrincione, A.
    VALUE IN HEALTH, 2007, 10 (06) : A334 - A334
  • [50] Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection
    Huang, Ming-Yii
    Huang, Chun-Ming
    Tsai, Hsiang-Lin
    Huang, Ching-Wen
    Hsieh, Hui-Min
    Yeh, Yung-Sung
    Wu, Jeng-Yih
    Wang, Wen-Ming
    Wang, Jaw-Yuan
    ONCOLOGY LETTERS, 2017, 14 (06) : 6754 - 6762
12345